ClinicalTrials.gg
RecruitingNCT07023315Updated Feb 11, 2026

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

A Phase 3 interventional study of Cadonilimab and SOX chemotherapy in Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, sponsored by Akeso. Recruiting at 6 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Adenocarcinoma with a site in China — 33 open to participants now, 42 under way, 12 of them phase 3. Adenocarcinoma · China.

Planned enrollment
5th of 68
760 · median 98
Started
2025
with 10 others
Phase 3
17 of 77
7 open now
Primary completion
2029-07
later than 37 of 41 live
Registered
62nd of 77
by date

Among the 77 studies in Adenocarcinoma with a site in China, this one is the 5th largest by planned enrollment of the 68 interventional ones that give a count, is one of 11 that started in 2025, is one of 17 in phase 3, reaches primary completion later than 37 of the 41 other live ones, and was the 62nd registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

33 of the 77 studies in Adenocarcinoma with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Adenocarcinoma with a site in China, or all of them as a file.
02

Study summary

This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.

Read the detailed description

This trial is a Phase 3 study. All patients are resectable gastric or gastroesophageal junction adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy for perioperative treatment of resectable gastric or gastroesophageal junction adenocarcinoma.

03

Conditions studied

  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed gastric or gastroesophageal junction adenocarcinoma with resectable disease (clinical stage T3-4aN+M0 or T4bNanyM0 per AJCC 8th edition).
  2. (ECOG) performance status of 0 or 1 at enrollment.
  3. Has of at least 6 months.
  4. Availability of tumor sample prior to study entry.
  5. Patients must undergo radical surgery.
  6. Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Patients with unresectable locally advanced disease or distant .
  2. Histopathology or cytology confirmed other pathological types, such as adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor.
  3. Current or prior use of medication within 14 days before randomization.
  4. Has received prior anti-cancer therapy for the current .
  5. Has an active infection requiring systemic therapy.
  6. to any of the study drugs.
  7. Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.
  8. Has an active disease that has required systemic treatment in past 2 years.
  9. Known active or virus infection.
  10. Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
760 participants (estimated)

Study arms

  • Experimental
    cadonilimab+SOX

    Cadonilimab plus Oxaliplatin and Tegafur-Gimeracil-Oteracil Potassium (SOX)

    Drug: Cadonilimab · Drug: SOX chemotherapy

  • Placebo comparator
    Placebo+SOX

    Placebo plus Oxaliplatin and Tegafur-Gimeracil-Oteracil Potassium (SOX)

    Drug: SOX chemotherapy · Drug: Placebo

Interventions

  • Anti-PD-1/ CTLA-4 tetrameric bispecific antibody

  • DrugSOX chemotherapy

    Drug pages: Tegafur · Gimeracil · Oxonic Acid · Oxaliplatin

    A combination treatment made up of oxaliplatin and tegafur-gimeracil-oteracil potassium

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS)

    EFS is the time from date of randomization until the date of disease progression or death.

    Time frame: Up to 5 years

  2. Pathological Complete Response (pathCR) Rate

    PathCR rate is defined as the percentage of participants having a pathCR assessed by the investigators. PathCR is defined as no invasive disease within an entirely submitted and evaluated gross lesion, and histologically negative nodes.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Overall survival (OS)

    Overall survival is length of time from randomization until the date of death due to any cause.

    Time frame: Up to 10 years

  2. Disease-free Survival (DFS)

    DFS is defined as the time from post-surgery baseline scan until the first occurrence of local or distant recurrence or death from any cause.

    Time frame: Up to 5 years

  3. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to 5 years

07

Study locations

6 of 6 sites recruiting
  • Peking University Cancer Hospital
    Beijing, Beijing Municipality 100143, China
    Recruiting
    • Jiafu Ji, MD · Principal investigator
    • Lin Shen, MD · Principal investigator
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian, China
    Recruiting
    • Luchuan Chen, MD · Principal investigator
  • Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
    • Qun Zhao, MD · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
    Recruiting
    • Yanqiao Zhang, MD · Principal investigator
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Yihong Sun, MD · Principal investigator
  • Tianjin Provincial Tumor Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting
    • Han Liang, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2029, 47 months after the start.

Of 26 phase 3 interventional studies under Adenocarcinoma, half reached primary completion within 91 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 101. This study's planned 47 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 16, 2025
StartActual
Aug 14, 2025
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2031
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07023315
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jun 16, 2025
Start date
Aug 14, 2025
Primary completion
Jul 2029 (estimated)
Completion
Jul 2031 (estimated)
Last update
Feb 11, 2026

Study contacts

Zhifang Yao, MD
Contact
clinicaltrials@akesobio.com
86-0760-89873999
Jiafu Ji, MD
Contact
jijiafu@hsc.pku.edu.cn

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion